纽约时报 摧毁阿片类药物之际 普渡制药家族嗅到了新的商机(3)（在线收听）

In 2009, two years after the federal guilty plea,

马萨诸塞州检察官援引的电子邮件往来记录显示，

Mortimer D.A. Sackler, a board member, demanded to know why the company wasn’t selling more opioids,

2009年，在签署联邦认罪协议两年后，

email traffic cited by Massachusetts prosecutors showed.

莫蒂默·萨克勒，普渡制药公司董事，还要求了解公司为何没有售出更多阿片类药物。

In 2011, as states looked for ways to curb opioid prescriptions,

2011年，各州都在想办法控制阿片类药物处方的数量时，

family members peppered the sales staff with questions about how to expand the market for the drugs.

萨克勒家族的成员还向销售人员提出了大量有关如何扩大阿片类药物市场的问题。

Mortimer asked if they could sell a generic version of OxyContin in order to "capture more cost sensitive patients," according to one email.

一封电子邮件显示，莫蒂默曾询问（销售人员)他们是否可以销售普通版的奥施康定，以“俘获更多对药费敏感的患者”。

Kathe, his half sister, suggested studying patients who had switched to OxyContin

莫蒂默同父异母的妹妹凯特曾建议，对那些改用奥施康定的病人展开研究，

to see if they could find patterns that could help them win new customers,

看看能否借此找到帮助他们赢得新客户的模式。

according to court filings in Massachusetts.

马萨诸塞州的法庭文件显示。

The family’s statement said they were just acting as responsible board members,

该家族的声明称，他们那么做只是在尽董事会成员的责任，

raising questions about "business issues that were highly relevant to doctors and patients."

对“与医生和病人高度相关的商业问题”提出他们的疑问。

In July 2011, Mortimer and Kathe’s cousin Dr. Richard Sackler,

2011年7月，莫蒂默和凯特的堂兄理查德·萨克勒医生,

who had stepped down as Purdue’s president several years earlier but remained an influential board member,

几年前，他辞去了普渡制药总裁一职，但依然是公司颇有分量的董事,

went into the field with a sales representative to promote opioids to doctors,

曾在销售代表的陪同下亲自找医生促销阿片类药物，

though some in the company were concerned that his involvement could run afoul of regulators,

虽然公司有员工担心他的亲力亲为会和监管机构发生冲突，

according to documents in the Massachusetts case.

麻萨诸塞州的诉讼文件显示。

When he returned, he argued in an email to Purdue’s vice president for sales

回去后，他在给普渡制药负责销售的副总裁的一封邮件中辩称，

that a legally required warning about opioids wasn’t needed,

没有必要按照法律要求对阿片类药物（的危险性）发出警告，

and that it "implies a danger of untoward reactions and hazards that simply aren’t there."

不然反而“相当于在暗示药物有事实上根本不存在的不良反应和危险”。

(The family’s statement disputed that, saying that Richard supported accurate labeling,

（该家族的声明对此作出了反驳，声称理查德是支持明确在标签里注明药物风险的，

and merely questioned where on the label the warning should appear.

只是对警告应该放在标签上的哪个位置提出了疑问。

The statement also said he had not been out in the field with sales representatives since well before the launch of OxyContin, in 1996.)

声明还说，1996年奥施康定推出之前，他就早已不再和销售代表一起跑业务了。)

In 2014, Raymond Sackler, now deceased, sent three other family members a confidential memo

2014年，现已去世的雷蒙德·萨克勒向家族其他三名成员发送了一份机密备忘录，

about Purdue’s strategy for placing patients on high doses of opioids for extended periods of time.

内容是关于普渡制药如何让患者长时间服用高剂量阿片类药物的策略。

The memo noted that doctors had argued against the practice,

备忘录指出，医生们反对这种做法，

but that Purdue had beaten back efforts to impose caps on doses,

但公司压制了对剂量设置上限的努力，

according to the Massachusetts complaint.

马萨诸塞州的起诉书显示。

The next year, Jonathan Sackler, then a board member,

次年，时任董事会成员的乔纳森·萨克勒

sought information about how public health campaigns to curb opioid addiction would affect OxyContin sales.

曾搜集过有关遏制阿片类药物成瘾的公共卫生运动将对奥施康定的销售造成怎样的影响方面的信息。

In 2017, he pushed to develop a new opioid, and asked the staff to present a plan at the next Purdue board meeting.

2017年，他力推开发一种新的阿片类药物，还要求员工在下一次普渡制药董事会会议上提交一份相关的方案。